Pharmaceutical

Accenture Invests in QuantHealth to Accelerate Use of AI-powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Accenture (NYSE: ACN) announced it has made a strategic investment, through Accenture Ventures, in…

12 months ago

BioHarvest Issues 2023 Year End Shareholder Letter and Provides Corporate Update

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 8, 2024) - BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE:…

12 months ago

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in…

12 months ago

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Advanced technology enables the land-based production of omega-3 (EPA+DHA) in Camelina potentially representing a novel solution to the market need…

12 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Achieving scale with pro forma full year 2023 revenue of approximately $192 millionSOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE…

12 months ago

Evaxion Announces Plan to Implement ADS Ratio Change

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

12 months ago

USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone…

12 months ago

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

12 months ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

12 months ago

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Announces senior leadership appointments to further support client programs and growing sales pipelineDURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) --…

12 months ago